Disclosure Of Non-Current Assets Held For Sale And Discontinued Operations [Text Block]

OSE Immunotherapeutics - Filing #831399

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Disclosure of non-current assets held for sale and discontinued operations [text block]
Disclosure of analysis of single amount of discontinued operations [text block]
Disclosure of analysis of single amount of discontinued operations [abstract]
Disclosure of analysis of single amount of discontinued operations [line items]
Profit (loss) before tax
23 221 EUR
18 022 EUR
Revenue
2 227 EUR
18 302 EUR
Cash flows from continuing and discontinued operations [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
19 764 EUR
18 252 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
507,000 EUR
26,000 EUR
Cash flows from (used in) financing activities [abstract]
Cash flows from (used in) financing activities
13 324 EUR
10 267 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.